NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Adrenoleukodystrophy (ALD)

https://www.minoryx.com/media/leriglitazone_receives_a_positive_chmp_opinion_for_the_treatment_of_cerebral_adrenoleukodystrophy

Minoryx Therapeutics and Neuraxpharm Group have announced that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd) negative brain lesions. Gadolinium is a clear liquid injected for contrast to enhance MRI scans, Gd negative means the scan did not show active disease. European Commission approval is expected by the end of September 2026.